title: A first-in-man study of sirolimus-eluting, biodegradable polymer coated cobalt chromium stent in real life patients.
abstract: BACKGROUND
  Despite considerable benefits associated with current drug-eluting stents, continued attention to the safety, efficacy, and deliverability of available drug-eluting stent has led to the development of newer stent.
  
  
  METHODS
  This study was a single-centre, prospective, non-randomized, first-in-man study which included clinical follow-up data was collected at 1, 8 and 12 months after the procedure. The study included 105 patients with de novo native coronary artery lesions including multi-vessel disease treated with Supralimus-Core® stent. Repeat angiography was performed 8 months post-stent implantation.
  
  
  RESULTS
  At quantitative coronary angiography 8-month luminal late loss was 0.39 ± 0.33 mm in-stent and 0.33 ± 0.35 mm in-segment. The incidence of any major adverse cardiac event at 30 days, 8 months and 12 months was 1 (1%), 6 (6%) and 7 (7%) respectively.
  
  
  CONCLUSIONS
  This study demonstrates that the Supralimus-Core® SES is a safe and effective treatment for patients with obstructive coronary artery disease. ClinicalTrials.gov ID: NCT00811616.
authors.affiliation: Escorts Heart Institute & Research Centre, New Delhi, India.
authors.forename: Ashok
authors.initials: A
authors.lastname: Seth
authors.forename: Praveen
authors.initials: P
authors.lastname: Chandra
authors.forename: Nagendra S
authors.initials: NS
authors.lastname: Chouhan
authors.forename: Ashok S
authors.initials: AS
authors.lastname: Thakkar
mesh_terms: D020341:Absorbable Implants; D002857:Chromium; D020099:Coated Materials, Biocompatible; D003035:Cobalt; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011108:Polymers; D011446:Prospective Studies; D020123:Sirolimus / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D020099:Coated Materials, Biocompatible; D007166:Immunosuppressive Agents; D011108:Polymers; D002857:Chromium; D003035:Cobalt; D020123:Sirolimus